Physician profile
Benjamin Butler
NPI 1245624279
$2,313.37
in general payments reported to CMS, 2019-2025
25 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $341 · 2023: $473 · 2024: $558 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $336.73 | 2022-2025 | Tezspire, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.16 | 2022-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $257.38 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $181.17 | 2022-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $166.82 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $137.07 | 2024-2025 | Winrevair |
| Harmony Biosciences LLC | $120.71 | 2022-2025 | Wakix |
| Grifols USA, LLC | $99.25 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Bayer Healthcare Pharmaceuticals INC. | $93.99 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.76 | 2023-2025 | Glassia |
| United Therapeutics Corporation | $84.24 | 2022 | |
| Genzyme Corporation | $78.14 | 2024-2025 | |
| Shionogi INC | $58.91 | 2023-2024 | Fetroja |
| Viatris Specialty LLC | $47.63 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $43.12 | 2024 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $41.88 | 2025 | Sunosi |
| Mylan Specialty L.P. | $36.00 | 2023-2024 | Yupelri |
| Abbvie INC. | $29.24 | 2023 | Avycaz, Teflaro |
| Haemonetics Corporation | $22.44 | 2024 | Teg6s Hemostasis System |
| Resmed Corp | $19.90 | 2024 | |
| Lilly USA, LLC | $19.23 | 2025 | Zepbound |
| Baxter Healthcare | $19.16 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $18.48 | 2023 | |
| Amgen INC. | $15.67 | 2025 | Tezspire |
| Pfizer INC. | $15.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.